Insights On Enterprise Solutions

  1. High-Yield MSC Expansion At The Forefront Of Cell Therapy Advancement 10/14/2026

    As MSC therapies move from autologous to allogeneic use and higher cell doses, the question shifts from efficacy to reliable expansion. See how design, closed handling, and media shape scale-up.

  2. All You Need To Know About GMP Manufacturing Of mRNA-LNP Drug Products 10/13/2026

    Moving mRNA-LNP production from lab to GMP scale exposes tensions among formulation consistency, regulatory expectations, and facility safety, while automation offers ways to resolve them.

  3. Top 5 Things To Know About The Lipid Nanoparticle Portfolio 10/13/2026

    Lipids that shift charge with pH can be chosen to fit the application and delivery route. Varied pKa and biodegradability give developers room to match each therapeutic target.

  4. Expand mRNA-LNP Nanomedicine Potential By Optimizing Lipids 10/13/2026

    Ionizable lipid selection ratios shape how well lipid nanoparticles deliver nucleic acids, and empirical testing shows that similar physical properties can still produce very different performance.

  5. Adherent PSC Expansion: Key Considerations For Scalable Manufacturing 10/13/2026

    Adherent multilayer vessels let PSC cultures scale without changing familiar media and handling, but coating volumes, seeding density, and harvest recovery all need rethinking.

  6. Improving Stability Through Science-Led OSD Reformulation 10/13/2026

    A marketed multivitamin tablet spanning a 0.03% to 46% w/w range failed early in accelerated stability testing. Mechanism-led reformulation and a switch to direct compression changed the outcome.

  7. De-Risking Complex Generic OSD Development 10/13/2026

    Complex generic tablet development requires early alignment of regulatory strategy, QbD formulation, discriminatory dissolution, and reference-scaled bioequivalence.

  8. Accelerating Complex Generic Drug Development Through Advanced Deformulation 10/13/2026

    With FDA no longer identifying Q1/Q2 differences, applicants bear the diagnostic burden. Reverse engineering now directly affects development speed, cost, and approval.

  9. Efficient Tech Transfer For Ultra-Scale Biomanufacturing 10/13/2026

    Biologics manufacturing is entering a fourth wave, driven by ultra-large bioreactors and outsourced production, where successful technology transfer is critical to scale, efficiency, and supply.

  10. Purification Process Development Of Plasmid DNA For Gene Therapy 10/13/2026

    Filter grades, precipitation, membrane cutoffs, and anion exchange formats are compared for purifying supercoiled plasmid DNA, with purity results that show how much each step contributes.